2020-11-08| Asia-Pacific

J&J Innovation Initiates Strategic Collaborations with Three Chinese Pharma Companies

by Judy Ya-Hsuan Lin
Share To

On November 6th, Johnson & Johnson Innovation, a division of J&J Investment Limited, announced three strategic collaborations with three Chinese pharmaceutical counterparts at the third China International Import Expo (CIIE) in Shanghai, China. Initiated by the J&J Asia Pacific Innovation Center, the collaborations attempt to demonstrate J&J Innovation’s strength in scientific innovation by addressing current unmet medical needs across drug discovery, lung cancer, and medical devices.

Dan Wang, Head of Johnson & Johnson Innovation, Asia Pacific, said, “at Johnson & Johnson Innovation, we recognize China as an important innovative hotspot in the Asia Pacific and are committed to deepening our support for the country’s healthcare ecosystem.” He continued, “these new collaborations demonstrate our commitment to building connections between entrepreneurs, researchers, biotech companies, and other innovators to accelerate innovation for the benefit of patients and consumers in China and the world for years to come.”


Why Innovate?

The collaborations simultaneously actualize J&J’s blueprint of delivering above-market growth set in the pharmaceutical business review last year. The collaborations will focus on three major directions:

  1. Delivering breakthrough medicines to meet the needs of patients around the world
  2. Maximizing potential leading brands by filing more than 40 line extensions for regulatory approval through 2023
  3. Building a strong pipeline that leverages data science, advanced therapeutic modalities, including cell and gene therapy, and an emphasis on diseases and biological pathways.

Chairman and CEO Alex Gorsky expressed his opinion during the meeting, claiming “our pharmaceutical organization has created breakthrough medicines to address some of society’s greatest unmet medical needs, resulting in meaningful outcomes and benefits to patients.” He added, “that progress must continue as we consider the future shape of healthcare. Greater transparency is already empowering families, leaders of healthcare systems, and insurers to make informed choices. Our broad base is well-positioned to continue delivering value-creating innovations that will improve outcomes.” Mr. Gorsky was responsible for six therapeutic areas, including immunology, infectious diseases and vaccines, neuroscience, cardiovascular and metabolism, oncology, and pulmonary hypertension.


Three Collaborative Strategies in 2020
  1. To showcase its drug discovery capability, J&J’s Janssen Pharmaceutica NV integrates established multi-target drug discovery with Hong Kong-based Insilico Medicine’s AI-based platform to develop new and patentable chemical scaffolds for difficult targets. This can greatly reduce the time and cost to sort biologically active forms of drugs that genuinely fight against the targets.
  2. Shanghai-based Diannei Biotechnology and J&J’s Lung Cancer Initiative division will focus on developing better lung cancer diagnoses. Since Diannei specializes in developing AI solutions with deep learning, J&J hopes to invent a computer vision AI for higher quality medical image analysis.
  3. Taikang Online Insurance partners with J&J’s Medical division for innovative healthcare solutions for sports injuries. Taikang is a Chinese online healthcare insurance company searching for innovative sports injury-related insurance packages with insightful industrial advice from J&J Medical. In doing so, Taikang could offer timely diagnosis and appropriate surgical treatment for patients.

Will Song, Global Senior Vice President, China Chairman, Johnson & Johnson, felt optimistic about these collaborations in China because “Johnson & Johnson has deep roots in China for the past 35 years to address the growing needs of patients and consumers.” Besides, “[J&J is] delighted to mark the third annual CIIE, a significant platform that supports the expansion, innovation, and internationalization of the Chinese business environment, by announcing these new collaboration agreements.”

By Judy Ya-Hsuan Lin

Related Article: Telix Pharma Partners With China Grand Pharma for Greater China Marketing



© All rights reserved. Collaborate with us:
Related Post
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
JPM 2024: Biotech Companies Mapping Out Their Future, and a New Round of M&A Spree Begins
GeneOnline’s Pick: Top 10 Global Industry News Stories in 2023 (Part 1)
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top